IJABR

International Journal of Advanced Biotechnology and Research (IJABR)
ISSN 0976-2612, Online ISSN 2278–599X,
Vol-9, Issue-4, 2018, pp129-134
http://www.bipublication.com

Research Article

Prevalence of urinary tract infections and its Immunogenicity.

Amna Atta[1], Linta Mahboob[1], Adeel Naeem[2],
Iqra Haroon[1], Arslan Akram[1], Zain Ul Abdeen[1]
and Syed Zeeshan Haider Naqvi[1]*

[1]Microbiology Section, Institute of Molecular Biology and Biotechnology (IMBB),
The University of Lahore, Defense road campus, Lahore
[2]Medical officer, National Hospital and Medical Centre, DHA Phase I, Lahore
***Corresponding Author:** Email: zeeshani67@yahoo.comTel: +92 333 5545167.

ABSTRACT:

Presence of bacterial pathogens in urinary tract prompts urinary tract infections. These bacterial pathogens can infect the human (urethra, kidney and bladder). Characterization of the UTI depends upon the skeletal seriousness, type of infection and risk factors. Uropathogenic E. coli are the causative operators and anchors to the bladder epithelial walls and begin colonizing there which brings about disturbance. A few cytokines and effectors additionally play an imperative part in innate defense mechanism. Women are at the extreme danger of suffering from disease because female urethra is shorter than male. Examinations of the UTIs incorporate a couple of testing methods. Distinctive types of anti-infection agents and different treatments are the viable strategy for treating UTIs. Due to the ineffectivity of these virulence diseases novel approaches are discovered.

Keywords: Urinary tract infection, epidemiology, uropathogenic E. coli, diagnosis, antimicrobial chemotherapy, nanotechnology.

[I] INTRODUCTION:

Urinary tract infections (UTI) are amongst the mostly widely spread bacterial contaminations, with approximately 12 million cases revealed in the U.S. every year that cost an expected $3.52 billion annually[1]. Approximately 1 in every 2 women will suffer from UTI once in their life, and almost 1 of every 3 women will have given anti-infection treatment for UTI before age 25. The clinical indications of symptomatic UTI incorporates disease prompted aggravation of the urethra (urethritis), urinary bladder (cystitis), and kidneys (pyelonephritis) and are analyzed by the existence of abnormal amount of microbes in the urine (bacteriuria) with number of side effects. Side effects of cystitis incorporate constant elimination of urine; painful sensation and pain while urination (dysuria), suprapubic illness as well as lower gut uneasiness, and pale as well as bloody bad odour urine[2].

[II] EPIDEMIOLOGY:

The transmission of the disease differs with several factors such as age, sex and genitourinary abnormalities. Uropathogens have particular specificities e.g. adhesion, siderophores and poisons that empower to colonize and infect the urinary tract. The reservoir of the UTIs includes *Escherichia coli*, *Proteus mirabilis*, *Staphylococcus saprophyticus*, *Staphylococcus epidermidis* and *Klebsiella pneumonia*[3].

[III] CLASSIFICATION ON THE BASIS OF SEX:

3.1. Epidemiology of men:

Urinary tract infections are rarely common in adult males. Causes of young male UTIs involve

prostatis, epididmytis, orchitis, pyelonephritis, cystitis, urethritis and urinary catheters. The persistent cause of UTI in men is dysuria which leads to burning sensation while urination [4]. The combination of dysuria, urinary recurrence and urinary direness is around 75% estimated for UTI though the intense beginning of reluctance, urinary spilling and moderate stream is just around 33% predictive for UTI.

3.2. Epidemiology of females:

UTIs are the most well-known type of clinical bacterial contamination. About 50- 60% of women experiences UTI once in their life. Post-menopausal women are at the more serious danger of causing the infection because of lack of oestrogen, pelvic prolapse and lack of lactobacilli in vaginal flora by *E. coli*. In non-pregnant female grownup intense uncomplicated UTI is considered to be a moderate sickness with no prolongedtreatment [3].

[IV] UROPATHOGENIC*Escherichia coli:*

Uropathogenic *E. coli* is the main diseased agent among all the other gram negative pathogens that cause UTI. *E. coli* is mainly found in the epithelial duct of animals and humans. *E. coli* makes synergistic combination with the host &performs effective part in maintaining the balance of microbial flora of luminal surface and sustaining the intestinal stability.As synergistic, *E. coli* preferably restricted to the abdominal lumen and uncommonly causes infection. Despite that, in the weakened or immunosuppressed host or when the epithelial ducts are broken, even virulent-synergistic specie of *E. coli* can spreadthe disease.

[V] TYPES OF VIRULENT FACTORS OF UPEC:

Uropathogenic *E. coli* acquires variety of virulent factors that empower the pathogens to multiply the walls of the urinary bladder and withstand in face of exceedingly successful host protection. These strains possess great amount of hereditary components, due to the control of particular virulent genes present on mobile hereditary components named as pathogenicity islands. Virulent factors are mainly of two types.

5.1. Surface virulent factors: These components involvevarious types of adhering organisms, which elevate the bacterial connection to the host tissue parts inside the urinary tract. Representation of these molecular substances by UPEC is the critical factor of pathogenicity. UPEC adhesions can cause destructiveness in various manners e.g. specifically activating bacterial and host cell signaling pathways, encouraging the conveyance of different virulent strains to the host tissues, facilitating bacterial violation [5].

Type 1 fimbriae empower the bacterial intrusion of the uro-epithelial cells where these pathogens repeat & build (IBCs) intracellular bacterial communities. That type of intrusion by the pathogens can happen after 1 to 4 hours of infection [6].

P-fimbriae are the 2nd important virulent component of UPEC, which assumes a critical part in the virulency of cystitis & pyelonephritis in human beings. These are important for the attachment of mucosal and tissue matrix furthermore, for the generation of cytokine factors. These virulent factors comprise of heteropolymeric filaments, formed of variety of subunits of proteins translated by papA-K gene operon. The P-fimbriae perceive kidney glycosphingolipids conveying the Gal α (1– 4) Gal determinant on the renal epithelia by means of its papG attachment. Adherence of these fimbriae to the receptors directs to the discharge of ceramide that behaves as a protagonist of TLR-4.This result in the increase of irritation and torment related with UTI [7].

S fimbriae are the 3rd most important virulent factor involved in the process of UTI. This form of virulent factor displays attachment to the endothelial and epithelial cell walls resulting from the cystitis and pyelonephritis.

Virulent factors present on the surface of the bacteria also involve the lipopolysaccharide and capsule. In order to protect the bacteria from host immune system capsule plays an important part. Capsule facilitates immunity against phagocytic engulfment & complemented-mediated bactericidal impact in the host. Several capsules e.g. K1 and K5 demonstrate a sub-atomic action to tissue parts, keeping an appropriate humoral insusceptible reaction of the infectious host[8].

5.1.1. Flagella:

Flagellum, as a part of bacterial motion is included in the cooperation of different virulent strains of *E. coli* with epithelium cells. 71-91% of urinary tract infections are cause by these flagellated UPEC strains. Also, their pathogenicity includes the association between the epithelial cells and bacteria of urinary tract[9].

5.1.2. Lipopolysaccharide:

Lipopolysaccharide is an important constituent of the cell wall of gram –ve bacterium. It plays an important part in the activation of host response and in the induction of nitric oxide and the production of cytokines. Despite the fact, LPS of the UPEC is vital in the initiation of pro-inflammatory reaction in the uncomplicated UTIs[10].

5.2. Secreted Virulence Factors:

Toxins are major virulent component in an assortment of *E. coli*-interceded illnesses. Formation of toxins by multiplying *E. coli* mediates an inflammation, a conceivable passage for UTIs manifestations. The major critical secreted virulence factor of UPEC is a lipoprotein termed as α- haemolysin (HlyA) which is related with pyelonephritis. HlyA is a pore-forming toxin that is most important in gram –ve bacteria. This toxin plays an important part to cause double concentration-dependent activities on epithelial cells arising from renal tubules [11]. At minimal concentration, HlyA can influence the killing of the target cells, involving T-lymphocytes, renal cells, neutrophils and boost the bladder walls exfoliation[12].

5.2.1 Cytotoxic Necrotising Factor1 (CNF1):

CNF1 is formed by the strains of pyelonephritis and involved in the kidney interruption. This proteinaceous material is emitted by *Escherichia coli* and empowers the production of actin fibers and layer ruffle production in the Rho GTPase-dependent form, bringing about the entrance of *E. coli* into the cells.

5.2.2. Secreted Auto-transporter Toxins (SAT):

SAT is a poisonous component of *E. coli* strains and has a virulent movement against cell wall of kidney & bladder, might be imperative for the pathogenicity of urinary tract infections. In addition to these virulent toxins cytolethal distending toxins (CDT) also be investigated as a part of the poisonous factors that causes UTIs[13].

[VI] INNATE IMMUNE DEFENSE MECHANISMOF UTIs:

The urinary tract is normally sterile, which is balanced by a number of host components to avoid the multiplication and survival of bacteria. Majority of the virulent strains, that causes UTI are from the host normal microbial flora and enter the bladder epithelial cells through the urethral lining. Attachment of UPEC strains is important for the advancements of UTIs. Uropathogenic *E. coli* plays an important part in the attachment that empowers the pathogens to colonize and adhere to the epithelial surface.

[VII] ANTIMICROBIAL PEPTIDES (AMPs):

Whenever *E. coli* are there in the urinary tract, they are moving by means of flagella. Prior to these microscopic organisms can append to the host cells, they might be attach by various antimicrobial peptides (AMPs) created by epithelial cells and phagocytic leukocytes. AMPs are the 1st line of defense to keep the pathogens from binding to the epithelial cells. Epithelial lining will quickly secrete AMPs when the nearness of microbes is detected. Different AMPs plays an enormous role in the disruption of bacterial cell membrane such as uromodulin, Defensins, Cathelicidin, lactoferrin, Hepcidin[14].

[VIII] TOLL-LIKE RECEPTORS:

They are trans-membrane proteins, only TLR4, 5, 11 play role in defense mechanism. TLR4 present on the epithelial cells of kidney, TLR5 on bladder and TLR11 on kidney cells. TLR4 activation results in the secretion of IL6, IL8. The response of TLR4 occurs by the activation NFκ-B or rise in intracellular Ca^{+2} results in the IL-6 secretion.

TLR5 response occurs by binding to flagella [15].

[IX] BLADDEREPITHELIAL CELL EXOFOLIATION:

The most important guards of the urinary tract are the fast exfoliation of epithelial cells because of the reaction of type 1-fimbrae attached to uroplakin. Adherence causes the uroplakin to be phosphorylated on its cytoplasmic tail. This causes the cascade to quickly increase the intra-cellular calcium and causes the cell death. This fast shedding is an endeavor to keep the microscopic organisms from having the capacity to attack the bladder cells. It is additionally a powerful method to disrupt the intracellular bacterial communities (IBCs) in those cells[16].

9.1. Other effectors and cytokines: Different types of effector and cytokines are produced as a result of inflammation such as IL-6, IL-17 A, 1L-8, G-CSF, IL-10 and Lipocalin 2.

9.2. Innate immune cells:

Innate immune cells consist of the neutrophils, macrophages, dendritic cells. Macrophages can phagocyte and produces pro-inflammatory molecules and toxic metabolites. Neutrophils kill the bacteria and dendritic cells acts as antigen presenting cells.

[X] CLINICAL DIAGNOSIS:

Clinical diagnoses of the UTIs include several procedures including previous medical history, urinalysis, biochemical testing, antibiotic sensitivity, microbial inhibitory count[17].

10.1. Previous history:

Clinical analysis of the urinary tract infections are usually depends upon the past medical history. Particular information may either increase or decrease the severity of infection.

10.2. Urine collection:

Different types of urine samples are collected e.g. mid-stream urine sample, clean-catch urine, and catheter specimen of urine, urethric aspiration and suprapubic aspiration which is commonly taken rarely. Dipstick method is the instrument for symptomatic testing if there is a medical confirmation that a patient is experiencing urinary tract infections[18].

10.3. Culturing of urine sample:

Urine sample was inoculated onto different media and incubated at 37°C for 24 hrs. Identification was usually based upon different biochemical tests. Microscopy was usually done to identify what type of strains present.

10.4. Antibiotic sensitivity test:

The bacterial isolates were subjected to antimicrobial sensitivity testing using the disc diffusion method. After this we can perform minimum inhibitory concentration.

[XI] RESISTANCE TO ANTIMICROBIAL DRUGS:

11.1. Trimethoprim-sulfamethoxazole:

Trimethoprim-sulfamethoxazole has for quite some time been considered the empirical treatment for intense & repetitive UTIs due to its severity against the most basic uropathogens and its low cost and tolerability. The synergistic mix of trimethoprim and sulfamethoxazole works at two different levels of the bacterial foliate digestion, resulting in DNA inhibition.

11.2. Fluoroquinolones:

Fluoroquinolones are the group of broad spectrum antibiotics that inhibit DNA gyrase and have excellent activity against gram negative Uropathogens. Ciprofloxacin and levofloxacin are the 2 generally normally utilized fluoroquinolones for UTIs and form negligible reactions. For example, sickness, looseness of the bowels, photosensitivity, and cerebral pain.

[XII] NANOTECHNOLOGY (A NOVEL APPROACH):

The microbial diseases have become an alarming medical problem because of the resistant strains of superbugs (Bacteria, Virus and fungi) this may leads to severe health issues, prolonged infections and less life expectancy. Due to the ineffectivity of these virulent agents there is the need to seek novel nanotechnologies and antimicrobials against these organisms. Due to the existence of new nanotechnologies they have started to develop novel or increasing the activity of conventional antimicrobials. Despite of their small size nanoparticles plays a critical role in the different fields of science. Nanoparticles are of different types, shapes and comprise of different synthesis routes. The physical properties and the chemical properties based upon the size, shape, electron motion

type, metallic nanoparticles, metal oxide nanoparticles, quantum dots, polymeric nanoparticles and carbon nanoparticles [19].

ACKNOWLEDEGEMENTS:

All the authors are thankful to the Department of IMBB/CRiMM, The University of Lahore for providing the better facilities. Especially to Dr. Zeeshan Haider Naqvi for providing us an opportunity to work on that topic. He provided us with help, support and guidance through all the ups and downs we have faced during the research work.

REFERENCES:

1. Griebling, T.L, (2005), Urologic diseases in America project: trends in resource use for urinary tract infections in women, J Urol. Vol-**173**, issue4, pg1281–7
2. Foxman, B, (2002), Epidemiology of urinary tract infections: incidence, morbidity, and economic costs, American Journal of Medicine.113(Suppl 1A):5S–13S.
3. Nicolle, L.E, Bradley, S, Colgan, R, Rice, J.C, Schaeffer, A, Hooton, T.M, (2005), Infectious diseases society of America guidelines for the diagnosis and treatment of asymptomatic bacteriuria in adults, Clinical Infectious Diseases. Vol-40, issue10, pg1556
4. Bremnor, J.D, Sadovsky, R, (2002),Evaluation of dysuria in adults, Am FAM Physician. Vol-6, issue8, pg 1589-1596
5. Hooton, T.M, Stamm, W.E, (1997), Diagnosis and treatment of uncomplicated urinary tract infection, Infectious Disease Clinics of North America. Vol-11, pg 551–81
6. Wagenlehner, F.M, Hoyme, U, Kaase, M, Fünfstück, R, Naber, K.G, Schmiemann, G, (2011), Uncomplicated Urinary Tract Infections, Deutsches Ärzteblatt International. Vol-108, issue24, pg415-423
7. Tonolini, M, Ippolito, S, (2016), Cross-sectional imaging of complicated urinary infections affecting the lower tract and male genital organs, Insights into Imaging. Vol-7, issue5, pg689-711
8. Kaper, J.B, Nataro, J.P, Mobley, H.L.T, (2004),Pathogenic Escherichia coli, Nature Reviews Microbiology. Vol-2, issue2, pg 123–140
9. Pichon, C, Hechard, C, Du, Merle, L, Chaudray, C, Bonne, I, Guadagnini, S, Vandewalle, A, Le, Bouguenec, C, (2009),Uropathogenic *Escherichia coli* AL511 requires flagellum to enter renal collecting duct cells, Cellular Microbiology. Vol-11, issue4, pg 616–628
10. Mulvey, M.A, (2002),Adhesion and entry of uropathogenic Escherichia coli, Cellular Microbiology. Vol-4, issue5, pg 257–271
11. Totsika, M, Moriel, D.G, Idris, A, Rogers, B.A, Wurpel, et al., (2012), Uropathogenic Escherichia coli mediated urinary tract infection, Curr Drug Targets. Vol-13, pg 1386-1399
12. Bergsten, G, Wullt, B, Svanborg, C, (2005),Escherichia coli, fimbriae, bacterial persistence and host response induction in the human urinary tract,International Journal of Medical Microbiology. Vol-295, issue6-7, pg 487-502
13. Johnson, J.R, (1991),Virulence factors in *Escherichia coli* urinary tract infection, Clinical Microbiology Reviews. Vol-4, issue1, pg 80-128
14. Ali, A.S, Townes, C.L, Hall, J, Pickard, R.S, (2009),Maintaining a sterile urinary tract: the role of antimicrobial peptides,J Urol. Vol-182, issue1, pg 21-8
15. Spencer, J.D, Schwaderer, A.L, Becknell, B, Watson, J, Hains, D.S, (2014),The innate immune response during urinary tract infection and pyelonephritis, Pediatric nephrology. Vol-29, issue7, pg 1139-49
16. Sivick, K.E, Mobley, H.L, (2010),Waging war against uropathogenic Escherichia coli: winning back the urinary tract, Infect Immun. Vol-78, issue2, pg 568-85
17. Schmiemann, G, Kniehl, E, Gebhardt, K, Matejczyk, M.M, Hummers-Pradier, E, (2010),The diagnosis of urinary tract infection: A Systematic Review, Dtsch

Ärzteblatt International.Vol-107, issue21, pg361-7

18. Wilson, M.L, Gaido, L, (2004), Laboratory diagnosis of urinary tract infections in adult patients, Clinical Infectious Diseases. Vol-38, issue8, pg1150-8
19. Naqvi, S.Z.H, Kiran, U, Ali, M.I, Jamal, A, Hameed, A, Ahmed, S, Ali, N,(2013), Combined efficacy of biologically synthesized silver nanoparticles and different antibiotics against multi-drug resistant bacteria, Int J Nanomedicine. Vol-8, pg3187-95